Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free BRBI Stock Alerts

BR Biopharma (BRBI) Financials

BR Biopharma logo
$11.44 -0.31 (-2.60%)
Closing price 07/16/2026 03:35 PM Eastern
Extended Trading
$11.74 +0.30 (+2.66%)
As of 07/16/2026 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BR Biopharma

Annual Income Statements for BR Biopharma

This table shows BR Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 22 11 16
Consolidated Net Income / (Loss)		 32 31 32
Net Income / (Loss) Continuing Operations		 22 11 16
Total Pre-Tax Income 		39 26 34
Total Operating Income		 -38 -44 -43
Total Gross Profit		 51 57 56
Total Revenue		 51 57 56
Operating Revenue		 51 57 56
Other Revenue		 0.36 0.20 0.39
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 89 101 99
Selling, General & Admin Expense		 15 22 22
Other Operating Expenses / (Income)		 74 79 78
Total Other Income / (Expense), net		 77 69 77
Interest Expense		 -78 -70 -77
Other Income / (Expense), net		 -0.95 -0.50 -0.15
Income Tax Expense		 17 15 18
Weighted Average Basic Shares Outstanding		 - - 200.55M
Weighted Average Diluted Shares Outstanding		 - - 200.55M
Weighted Average Basic & Diluted Shares Outstanding		 - - 200.55M

Quarterly Income Statements for BR Biopharma

No quarterly income statements for BR Biopharma are available.

Annual Cash Flow Statements for BR Biopharma

This table details how cash moves in and out of BR Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 190 76 -147
Net Cash From Operating Activities		 33 76 34
Net Cash From Continuing Operating Activities		 33 76 34
Net Income / (Loss) Continuing Operations		 32 31 32
Consolidated Net Income / (Loss)		 32 31 32
Depreciation Expense		 1.39 1.21 1.98
Net Cash From Investing Activities		 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00
Net Cash From Financing Activities		 157 0.00 -181
Net Cash From Continuing Financing Activities		 157 0.00 -181
Other Financing Activities, net		 157 - -181
Cash Interest Paid		 135 - 248
Cash Interest Received		 170 200 252

Quarterly Cash Flow Statements for BR Biopharma

No quarterly cash flow statements for BR Biopharma are available.

Annual Balance Sheets for BR Biopharma

This table presents BR Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 2,435 3,192
Total Current Assets		 90 34
Note & Lease Receivable		 - 34
Plant, Property, & Equipment, net		 6.84 8.08
Total Noncurrent Assets		 2,341 5,121
Intangible Assets		 2.51 2.24
Noncurrent Deferred & Refundable Income Taxes		 15 17
Other Noncurrent Operating Assets		 2,323 5,102
Total Liabilities & Shareholders' Equity		 2,210 5,157
Total Liabilities		 2,305 3,049
Total Current Liabilities		 4.64 25
Other Taxes Payable		 2.07 3.65
Other Current Liabilities		 - 22
Total Noncurrent Liabilities		 180 5,132
Noncurrent Deferred & Payable Income Tax Liabilities		 24 34
Other Noncurrent Operating Liabilities		 212 5,098
Total Equity & Noncontrolling Interests		 130 0.00
Total Preferred & Common Equity		 130 0.00
Total Common Equity		 130 0.00

Quarterly Balance Sheets for BR Biopharma

No quarterly balance sheets for BR Biopharma are available.

Annual Metrics And Ratios for BR Biopharma

This table displays calculated financial ratios and metrics derived from BR Biopharma's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00
Growth Metrics		 - - -
Revenue Growth		 0.00% 11.76% -0.86%
EBITDA Growth		 0.00% -15.35% 4.39%
EBIT Growth		 0.00% -14.35% 2.54%
NOPAT Growth		 0.00% 12.79% -7.65%
Net Income Growth		 0.00% -2.02% 2.07%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% 127.37% -55.23%
Free Cash Flow Firm Growth		 0.00% 0.00% 197.91%
Invested Capital Growth		 0.00% 0.00% -99.74%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 100.00%
EBITDA Margin		 -73.33% -75.68% -72.99%
Operating Margin		 -74.20% -76.94% -76.23%
EBIT Margin		 -76.06% -77.82% -76.50%
Profit (Net Income) Margin		 62.81% 55.06% 56.69%
Tax Burden Percent		 81.41% 121.74% 93.67%
Interest Burden Percent		 -101.44% -58.12% -79.12%
Effective Tax Rate		 42.97% 57.08% 52.96%
Return on Invested Capital (ROIC)		 0.00% -1.78% -1.92%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 3.29% 3.35%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 49.93% 51.05%
Return on Equity (ROE)		 0.00% 48.14% 49.14%
Cash Return on Invested Capital (CROIC)		 0.00% -201.78% 197.06%
Operating Return on Assets (OROA)		 0.00% -1.82% -1.53%
Return on Assets (ROA)		 0.00% 1.29% 1.14%
Return on Common Equity (ROCE)		 0.00% 48.14% 49.14%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -19 -20
NOPAT Margin		 -42.32% -33.02% -35.86%
Net Nonoperating Expense Percent (NNEP)		 0.00% -5.07% -5.27%
Return On Investment Capital (ROIC_SIMPLE)		 - -25.36% 0.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 29.18% 38.85% 38.53%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 174.20% 176.94% 176.23%
Earnings before Interest and Taxes (EBIT)		 -39 -44 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 -43 -41
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 49.36
Price to Earnings (P/E)		 0.00 0.00 173.38
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.58%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 517.46
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 49.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 82.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 1.34
Leverage & Solvency		 - - -
Debt to Equity		 0.00 -0.43 0.00
Long-Term Debt to Equity		 0.00 -0.43 0.00
Financial Leverage		 0.00 15.18 15.22
Leverage Ratio		 0.00 18.71 43.25
Compound Leverage Factor		 0.00 -10.88 -34.22
Debt to Total Capital		 0.00% -75.65% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% -75.65% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 175.65% 0.00%
Debt to EBITDA		 0.00 1.30 0.00
Net Debt to EBITDA		 0.00 3.46 0.00
Long-Term Debt to EBITDA		 0.00 1.30 0.00
Debt to NOPAT		 0.00 2.98 0.00
Net Debt to NOPAT		 0.00 7.94 0.00
Long-Term Debt to NOPAT		 0.00 2.98 0.00
Altman Z-Score		 0.00 0.00 0.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.00 19.47 1.33
Quick Ratio		 0.00 20.03 1.33
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2,124 2,080
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.02 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 8.31 7.55
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 2,105 5.38
Invested Capital Turnover		 0.00 0.05 0.05
Increase / (Decrease) in Invested Capital		 0.00 2,105 -2,100
Enterprise Value (EV)		 0.00 0.00 2,783
Market Capitalization		 0.00 0.00 2,783
Book Value per Share		 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $0.00 $0.00 ($0.01)
Total Capital		 0.00 74 0.00
Total Debt		 0.00 -56 0.00
Total Long-Term Debt		 0.00 -56 0.00
Net Debt		 0.00 -149 0.00
Capital Expenditures (CapEx)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -7.24 8.42
Debt-free Net Working Capital (DFNWC)		 0.00 86 8.42
Net Working Capital (NWC)		 0.00 86 8.42
Net Nonoperating Expense (NNE)		 -53 -50 -52
Net Nonoperating Obligations (NNO)		 0.00 1,975 5.38
Total Depreciation and Amortization (D&A)		 1.39 1.21 1.98
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -12.72% 14.94%
Debt-free Net Working Capital to Revenue		 0.00% 150.83% 14.94%
Net Working Capital to Revenue		 0.00% 150.83% 14.94%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 200.55M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 200.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 200.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -31 -30
Normalized NOPAT Margin		 -42.32% -53.86% -53.36%
Pre Tax Income Margin		 77.15% 45.23% 60.52%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BR Biopharma

No quarterly metrics and ratios for BR Biopharma are available.


Financials Breakdown Chart

BR Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BR Biopharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

BR Biopharma's net income were at $31.97 million at the end of 2025, a 2.1% increase from 2024, and a 0.0% increase since 2023. View BR Biopharma's forecast to see where analysts expect BR Biopharma to go next.

BR Biopharma's total operating income in 2025 was -$42.98 million, based on the following breakdown:
  • Total Gross Profit: $56.38 million
  • Total Operating Expenses: $99.37 million

Over the last 2 years, BR Biopharma's total revenue changed from $50.89 million in 2023 to $56.38 million in 2025, a change of 10.8%.

BR Biopharma's total liabilities were at $3.05 billion at the end of 2025, a 32.3% increase from 2024, and a 32.3% increase since 2024.

Over the last 2 years, BR Biopharma's book value per share changed from 0.00 in 2023 to 0.00 in 2025, a change of 0.0%.


Related Companies

Financial statements for NASDAQ:BRBI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel